MIF in atherosclerosis

The MIF Handbook

Volumn , Issue , 2012, Pages 321-345

  Noels, Heidi ^a   Bernhagen, Jürgen ^a   Weber, Christian ^b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874773149     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9789814335362_0017     Document Type: Chapter

References (107)

1. David JR. (1966) Delayed hypersensitivity in vitro: Its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 56: 72-77.
2. Bernhagen J, Krohn R, Lue H et al. (2007) MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 13: 587-596.
3. Frascaroli G, Varani S, Blankenhorn N et al. (2009) Human cytomegalovirus paralyzes macrophage motility through down-regulation of chemokine receptors, reorganization of the cytoskeleton, and release of macrophage migration inhibitory factor. J Immunol 182: 477-488.
4. Morand EF, Leech M, Bernhagen J. (2006) MIF: A new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 5: 399-410.
5. Bernhagen J, Calandra T, Mitchell RA et al. (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365: 756-759.
6. Calandra T, Echtenacher B, Le Roy D et al. (2000) Protection from septic shock by neutralization of macrophage migration inhibitory factor (MIF). Nat Med 6: 164-169.
7. Mizue Y, Ghani S, Leng L et al. (2005) Role for macrophage migration inhibitory factor in asthma. Proc Natl Acad Sci USA 102: 14410-14415.
8. Donnelly SC, Haslett C, Reid PT et al. (1997) Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med 3: 320-323.
9. Burger-Kentischer A, Goebel H, Seiler R et al. (2002) Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation 105: 1561-1566.
10. Hansson GK, Libby P. (2006) The immune response in atherosclerosis: A double-edged sword. Nat Rev Immunol 6: 508-519.
11. Weber C, Zernecke A, Libby P. (2008) The multifaceted contributions of leukocyte subsets to atherosclerosis: Lessons from mouse models. Nat Rev Immunol 8: 802-815.
12. Zernecke A, Weber C. (2010) Chemokines in the vascular inflammatory response of atherosclerosis. Cardiovasc Res 86: 192-201.
13. Calandra T, Roger T. (2003) Macrophage migration inhibitory factor: A regulator of innate immunity. Nat Rev Immunol 3: 791-800.
14. Kim S, Miska KB, Jenkins MC et al. (2010) Molecular cloning and functional characterization of the avian macrophage migration inhibitory factor (MIF). Dev Comp Immunol 34: 1021-1032.
15. Sun HW, Bernhagen J, Bucala R, Lolis E. (1996) Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sci USA 93: 5191-5196.
16. Mischke R, Kleemann R, Brunner H, Bernhagen J. (1998) Cross-linking and mutational analysis of the oligomerization state of the cytokine macrophage migration inhibitory factor (MIF). FEBS Lett 427: 85-90.
17. Philo JS, Yang TH, LaBarre M. (2004) Re-examining the oligomerization state of macrophage migration inhibitory factor (MIF) in solution. Biophys Chem 108: 77-87.
18. Weiser WY, Temple DM, Witek-Gianotti JS et al. (1989) Molecular cloning of cDNA encoding a human macrophage migration inhibtion factor. Proc Natl AcadSci USA 86: 7522-7526.
19. Muhlhahn P, Bernhagen J, Czisch M et al. (1996) NMR characterization of structure, backbone dynamics, and glutathione binding of the human macrophage migration inhibitory factor (MIF). Protein Sci 5: 2095-2103.
20. Murphy PM, Baggiolini M, Charo IF et al. (2000) International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52: 145-176.
21. Hebert CA, Vitangcol RV, Baker JB. (1991) Scanning mutagenesis of interleukin-8 identifies a cluster of residues required for receptor binding. J Biol Chem 266: 18989-18994.
22. Rajagopalan L, Rajarathnam K. (2006) Structural basis of chemokine receptor function — A model for binding affinity and ligand selectivity. Biosci Rep 26: 325-339.
23. Kraemer S, Lue H, Zernecke A et al. (2011) MIF-chemokine receptor interactions in atherogenesis are dependent on an N-loop-based 2-site binding mechanism. FASEB J 25: 894-906.
24. Weber C, Koenen RR. (2006) Fine-tuning leukocyte responses: Towards a che-mokine 'interactome'. Trends Immunol 27: 268-273.
25. Wakasugi K, Schimmel P. (1999) Two distinct cytokines released from a human aminoacyl-tRNA synthetase. Science 284: 147-151.
26. Wakasugi K, Slike BM, Hood J et al. (2002) Induction of angiogenesis by a fragment of human tyrosyl-tRNA synthetase. J Biol Chem 277: 20124-20126.
27. Yang XL, Skene RJ, McRee DE, Schimmel P. (2002) Crystal structure of a human aminoacyl-tRNA synthetase cytokine. Proc Natl Acad Sci USA 99: 15369-15374.
28. Howard OM, Dong HF, Yang D et al. (2002) Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med 196: 781-791.
29. Yang D, Chertov O, Bykovskaia SN et al. (1999) Beta-defensins: Linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286: 525-528.
30. Hoover DM, Boulegue C, Yang D et al. (2002) The structure of human macrophage inflammatory protein-3alpha/CCL20. Linking antimicrobial and CC chemokine receptor-6-binding activities with human beta-defensins. J Biol Chem 277: 37647-37654.
31. Noels H, Bernhagen J, Weber C. (2009) Macrophage migration inhibitory factor: A noncanonical chemokine important in atherosclerosis. Trends Cardiovasc Med 19: 76-86.
32. Kleemann R, Kapurniotu A, Frank RW et al. (1998) Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidore-ductase. J Mol Biol 280: 85-102.
33. Thiele M, Bernhagen J. (2005) Link between macrophage migration inhibitory factor and cellular redox regulation. Antioxid Redox Signal 7: 1234-1248.
34. Esumi N, Budarf M, Ciccarelli L et al. (1998) Conserved gene structure and genomic linkage for D-dopachrome tautomerase (DDT) and MIF. Mamm Genome 9: 753-757.
35. Rosengren E, Bucala R, Aman P et al. (1996) The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol Med 2: 143-149.
36. Dios A, Mitchell RA, Aljabari B et al. (2002) Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity. J Med Chem 45: 2410-2416.
37. Senter PD, Al-Abed Y, Metz CN et al. (2002) Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc Natl Acad Sci USA 99: 144-149.
38. Ouertatani-Sakouhi H, El-Turk F, Fauvet B et al. (2009) A new class of isothiocyanate-based irreversible inhibitors of macrophage migration inhibitory factor. Biochemistry 48: 9858-9870.
39. Ouertatani-Sakouhi H, El-Turk F, Fauvet B et al. (2010) Identification and characterization of novel classes of macrophage migration inhibitory factor (MIF) inhibitors with distinct mechanisms of action. J Biol Chem 285: 26581-26598.
40. Calandra T, Bernhagen J, Mitchell RA, Bucala R. (1994) The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179: 1895-1902.
41. Calandra T, Spiegel LA, Metz CN, Bucala R. (1998) Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. Proc Natl Acad Sci USA 95: 11383-11388.
42. Takahashi M, Nishihira J, Shimpo M et al. (2001) Macrophage migration inhibitory factor as a redox-sensitive cytokine in cardiac myocytes. Cardiovasc Res 52: 438-445.
43. Miller EJ, Li J, Leng L et al. (2008) Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature 451: 578-582.
44. Simons D, Grieb G, Hristov M et al. (2011) Hypoxia-induced endothelial secretion of macrophage migration inhibitory factor and role in endothelial progenitor cell recruitment. J Cell Mol Med 15: 668-678.
45. Schmeisser A, Marquetant R, Illmer T et al. (2005) The expression of macrophage migration inhibitory factor 1alpha (MIF 1alpha) in human atherosclerotic plaques is induced by different proatherogenic stimuli and associated with plaque instability. Atherosclerosis 178: 83-94.
46. Flieger O, Engling A, Bucala R et al. (2003) Regulated secretion of macrophage migration inhibitory factor is mediated by a non-classical pathway involving an ABC transporter. FEBS Lett 551: 78-86.
47. Keller M, Ruegg A, Werner S, Beer HD. (2008) Active caspase-1 is a regulator of unconventional protein secretion. Cell 132: 818-831.
48. Merk M, Baugh J, Zierow S et al. (2009) The Golgi-associated protein p115 mediates the secretion of macrophage migration inhibitory factor. J Immunol 182: 6896-6906.
49. Lue H, Thiele M, Franz J et al. (2007) Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 26: 5046-5059.
50. Lan HY, Bacher M, Yang N et al. (1997) The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med 185: 1455-1465.
51. Gregory JL, Leech MT, David JR et al. (2004) Reduced leukocyte-endothelial cell interactions in the inflamed microcirculation of macrophage migration inhibitory factor-deficient mice. Arthritis Rheum 50: 3023-3034.
52. Lin SG, Yu XY, Chen YX et al. (2000) De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits. Circ Res 87: 1202-1208.
53. Pan JH, Sukhova GK, Yang JT et al. (2004) Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 109: 3149-3153.
54. Burger-Kentischer A, Gobel H, Kleemann R et al. (2006) Reduction of the aortic inflammatory response in spontaneous atherosclerosis by blockade of macrophage migration inhibitory factor (MIF). Atherosclerosis 184: 28-38.
55. Chen Z, Sakuma M, Zago AC et al. (2004) Evidence for a role of macrophage migration inhibitory factor in vascular disease. Arterioscler Thromb Vasc Biol 24: 709-714.
56. Schober A, Bernhagen J, Thiele M et al. (2004) Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation 109: 380-385.
57. Weber C. (2003) Novel mechanistic concepts for the control of leukocyte transmigration: Specialization of integrins, chemokines, and junctional molecules. J Mol Med 81: 4-19.
58. Laudanna C, Alon R. (2006) Right on the spot. Chemokine triggering of integrin-mediated arrest of rolling leukocytes. Thromb Haemost95: 5-11.
59. Leng L, Metz CN, Fang Y et al. (2003) MIF signal transduction initiated by binding to CD74. J Exp Med 197: 1467-1476.
60. Shi X, Leng L, Wang T et al. (2006) CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 25: 595-606.
61. Schwartz V, Lue H, Kraemer S et al. (2009) A functional heteromeric MIF receptor formed by CD74 and CXCR4. FEBS Lett 583: 2749-2757.
62. Lue H, Dewor M, Leng L et al. (2011) Activation of the JNK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on CXCR4 and CD74. Cell Signal 23: 135-144.
63. Koenen RR, Weber C. (2010) Therapeutic targeting of chemokine interactions in atherosclerosis. Nat Rev Drug Discov 9: 141-153.
64. Gregory JL, Morand EF, McKeown SJ et al. (2006) Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2. J Immunol 177: 8072-8079.
65. Lue H, Kapurniotu A, Fingerle-Rowson G et al. (2006) Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal 18: 688-703.
66. Mitchell RA, Metz CN, Peng T, Bucala R. (1999) Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 274: 18100-18106.
67. Goppelt-Struebe M, Rehfeldt W. (1992) Glucocorticoids inhibit TNF alpha-induced cytosolic phospholipase A2 activity. Biochim Biophys Acta 1127: 163-167.
68. Calandra T, Bernhagen J, Metz CN et al. (1995) MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377: 68-71.
69. Donnelly SC, Bucala R. (1997) Macrophage migration inhibitory factor: A regulator of glucocorticoid activity with a critical role in inflammatory disease. Mol Med Today 3: 502-507.
70. Kleemann R, Hausser A, Geiger G et al. (2000) Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 408: 211-216.
71. Qi D, Hu X, Wu X et al. (2009) Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion. J Clin Invest 119(12): 3807-3816.
72. Binsky I, Haran M, Starlets D et al. (2007) IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci USA 104: 13408-13413.
73. Mitchell RA, Liao H, Chesney J et al. (2002) Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response. Proc Natl Acad Sci USA 99: 345-350.
74. Jung H, Seong HA, Ha H. (2008) Critical role of cysteine residue 81 of macrophage migration inhibitory factor (MIF) in MIF-induced inhibition of p53 activity. J Biol Chem 283: 20383-20396.
75. Liu L, Chen J, Ji C et al. (2008) Macrophage migration inhibitory factor (MIF) interacts with Bim and inhibits Bim-mediated apoptosis. Mol Cells 26: 193-199.
76. Liu L, Ji C, Chen J et al. (2008) A global genomic view of MIF knockdownmediated cell cycle arrest. Cell Cycle 7: 1678-1692.
77. Liao H, Bucala R, Mitchell RA. (2003) Adhesion-dependent signaling by macrophage migration inhibitory factor (MIF). J Biol Chem 278: 76-81.
78. Bittl JA. (1996) Advances in coronary angioplasty. N Engl J Med 335: 1290-1302.
79. Korshunov VA, Nikonenko TA, Tkachuk VA et al. (2006) Interleukin-18 and macrophage migration inhibitory factor are associated with increased carotid intima-media thickening. Arterioscler Thromb Vasc Biol 26: 295-300.
80. Donn RP, Shelley E, Ollier WE, Thomson W. (2001) A novel 5'-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 44: 1782-1785.
81. Herder C, Illig T, Baumert J et al. (2008) Macrophage migration inhibitory factor (MIF) and risk for coronary heart disease: Results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Atherosclerosis 200: 380-388.
82. Palomino-Morales R, Gonzalez-Juanatey C, Vazquez-Rodriguez TR et al. (2010) Lack of association between macrophage migration inhibitory factor-173 gene polymorphism with disease susceptibility and cardiovascular risk in rheumatoid arthritis patients from northwestern Spain. Clin Exp Rheumatol 28: 68-72.
83. Makino A, Nakamura T, Hirano M et al. (2010) High plasma levels of macrophage migration inhibitory factor are associated with adverse long-term outcome in patients with stable coronary artery disease and impaired glucose tolerance or type 2 diabetes mellitus. Atherosclerosis 213: 573-578.
84. Tereshchenko IP, Petrkova J, Mrazek F et al. (2009) The macrophage migration inhibitory factor (MIF) gene polymorphism in Czech and Russian patients with myocardial infarction. Clin Chim Acta 402: 199-202.
85. Chen L, Yang G, Zhang X et al. (2009) Induction of MIF expression by oxidized LDL via activation of NF-kB in vascular smooth muscle cells. Atherosclerosis 207: 428-433.
86. Atsumi T, Nishihira J, Makita Z, Koike T. (2000) Enhancement of oxidised low-density lipoprotein uptake by macrophages in response to macrophage migration inhibitory factor. Cytokine 12: 1553-1556.
87. Bernhagen J, Mitchell RA, Calandra T et al. (1994) Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 33: 14144-14155.
88. Mercer J, Figg N, Stoneman V et al. (2005) Endogenous p53 protects vascular smooth muscle cells from apoptosis and reduces atherosclerosis in ApoE knockout mice. Circ Res 96: 667-674.
89. Schweitzer K, Bozko PM, Dubiel W, Naumann M. (2007) CSN controls NF-kappaB by deubiquitinylation of IkappaBalpha. EMBO J 26: 1532-1541.
90. Collins T, Cybulsky MI. (2001) NF-kappaB: Pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 107: 255-264.
91. de Winther MP, Kanters E, Kraal G, Hofker MH. (2005) Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vasc Biol 25: 904-914.
92. Kong YZ, Huang XR, Ouyang X et al. (2005) Evidence for vascular macrophage migration inhibitory factor in destabilization of human atherosclerotic plaques. Cardiovasc Res 65: 272-282.
93. Kong YZ, Yu X, Tang JJ et al. (2005) Macrophage migration inhibitory factor induces MMP-9 expression: Implications for destabilization of human atherosclerotic plaques. Atherosclerosis 178: 207-215.
94. Lemaitre V, O'Byrne TK, Borczuk AC et al. (2001) ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. J Clin Invest 107: 1227-1234.
95. Johnson JL, George SJ, Newby AC, Jackson CL. (2005) Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci USA 102: 15575-15580.
96. Verschuren L, Lindeman JH, van Bockel JH et al. (2005) Up-regulation and coexpression of MIF and matrix metalloproteinases in human abdominal aortic aneurysms. Antioxid Redox Signal 7: 1195-1202.
97. Schrans-Stassen BH, Lue H, Sonnemans DG et al. (2005) Stimulation of vascular smooth muscle cell migration by macrophage migration inhibitory factor. Antioxid Redox Signal 7: 1211-1216.
98. Lievens D, Eijgelaar WJ, Biessen EA et al. (2009) The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thromb Haemost 102: 206-214.
99. Amin MA, Volpert OV, Woods JM et al. (2003) Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphati-dylinositol kinase. Circ Res 93: 321-329.
100. Chesney J, Metz C, Bacher M et al. (1999) An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med 5: 181-191.
101. Ogawa H, Nishihira J, Sato Y et al. (2000) An antibody for macrophage migration inhibitory factor suppresses tumour growth and inhibits tumour-associated angiogenesis. Cytokine 12: 309-314.
102. Garai J, Lorand T. (2009) Macrophage migration inhibitory factor (MIF) tautomerase inhibitors as potential novel anti-inflammatory agents: Current developments. Curr Med Chem 16: 1091-1114.
103. Nickel W. (2010) Pathways of unconventional protein secretion. Curr Opin Biotechnol 21: 621-626.
104. Nickel W, Rabouille C. (2009) Mechanisms of regulated unconventional protein secretion. Nat Rev Mol Cell Biol 10: 148-155.
105. Nickel W, Seedorf M. (2008) Unconventional mechanisms of protein transport to the cell surface of eukaryotic cells. Annu Rev Cell Dev Biol 24: 287-308.
106. Horuk R, Proudfoot AE. (2009) Drug discovery targeting the chemokine system — Where are we? Front Biosci (Elite Ed) 1: 209-219.
107. Weber C, Kraemer S, Drechsler M et al. (2008) Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment. Proc Natl Acad Sci USA 105: 16278-16283.